Tumor recurrence after curative resection remains a major problem in patients with locally advanced colorectal cancer treated with adjuvant chemotherapy. Genetic single-nucleotide polymorphisms (SNP) may serve as useful molecular markers to predict clinical outcomes in these patients and identify targets for future drug development. Recent in vitro and in vivo studies have demonstrated that the plastin genes PLS3 and LCP1 are overexpressed in colon cancer cells and play an important role in tumor cell invasion, adhesion, and migration. Hence, we hypothesized that functional genetic variations of plastin may have direct effects on the progression and prognosis of locally advanced colorectal cancer. We tested whether functional tagging polymorphisms of PLS3 and LCP1 predict time to tumor recurrence (TTR) in 732 patients (training set, 234; validation set, 498) with stage II/III colorectal cancer. The PLS3 rs11342 and LCP1 rs4941543 polymorphisms were associated with a significantly increased risk for recurrence in the training set. PLS3 rs6643869 showed a consistent association with TTR in the training and validation set, when stratified by gender and tumor location. Female patients with the PLS3 rs6643869 AA genotype had the shortest median TTR compared with those with any G allele in the training set [1.7 vs. 9.4 years; HR, 2.84; 95% confidence interval (CI), 1.32-6.1; P ¼ 0.005] and validation set (3.3 vs. 13.7 years; HR, 2.07; 95% CI, 1.09-3.91; P ¼ 0.021). Our findings suggest that several SNPs of the PLS3 and LCP1 genes could serve as gender-and/or stage-specific molecular predictors of tumor recurrence in stage II/III patients with colorectal cancer as well as potential therapeutic targets. Mol Cancer Ther; 13(2); 1-12. Ó2013 AACR.
Introduction
Colorectal cancer is the leading cause of death from gastrointestinal malignancy, with approximately 50,830 deaths expected in 2013 (1) . Surgical resection affords the only chance for cure, and adjuvant chemotherapy is recommended for high-risk stage II and all stage III tumors as it reduces risk of recurrence and prolongs disease-free survival (2, 3) . However, even with adjuvant chemotherapy, 20% to 30% of high-risk stage II and 50% to 65% of stage III patients relapse within 5 years. Disease recurrence and survival are related to tumor histology, grade, and stage. Such conventional clinicopathologic staging has served as the standard measure of prognosis for many years. We have yet to identify reliable molecular markers to predict tumor recurrence in patients with stage II-III disease who have received adjuvant chemotherapy.
Although a number of genes have been implicated in colorectal cancer metastasis, the precise mechanisms directing the migration and invasion of tumor cells into specific organs remain elusive. Modulation of the actin cytoskeleton is critical for tumor cell migration and invasion (4) , and changes in the actin cytoskeleton are accomplished by a variety of actin-binding proteins, such as plastins (4, 5) . Moreover, increasing evidence suggests that overexpression of plastins in cultured epithelial cells can increase cell motility (6) . Therefore, plastins may not only be a potential biomarker but also serve as a valuable target for inhibiting tumor cell invasion and metastasis.
The human plastin family is composed of three protein isoforms: T-plastin (PLS3), L-plastin (LCP1), and I-plastin. I-plastin is specifically expressed in the small intestine and kidney. The cell-type-specific expression of the other isoforms (PLS3 and LCP1) is regulated under physiologic conditions. However, ectopic expression of plastins in malignant cells has been observed in many studies (7, 8) . PLS3 and LCP1, which have 80% amino acid homology, also share the unique property of cross-linking actin filaments into tight bundles. Although PLS3 and LCP1 are related in structure and function, they are encoded by two distinct genes located on chromosomes X and 13, respectively (9) , and possess other unique features. Specifically, PLS3 is expressed in a wide variety of cells except for hematopoietic cells. Most neoplastic cells derived from solid tumors also express PLS3. Conversely, LCP1 is expressed in most human cancer and hematopoietic cell lines (7) . PLS3 upregulation by the lamina A filament protein has been correlated with increased invasiveness in colorectal cancer (10) , and LCP1 overexpression plays a significant role in proliferation and invasion in colon cancer cell lines (11) . Furthermore, LCP1 has been proposed to mediate cell adhesion and motility by binding actin (9, 12) . However, little is known about the role of PLS3 and LCP1 in colorectal tumor metastasis.
Previously, data from our group and others have shown that certain genetic polymorphisms may predict clinical outcomes in patients with colon cancer treated with adjuvant chemotherapy (13, 14) . These common single nucleotide variations may alter gene transcription, translation, or splicing, thereby causing different tumor recurrence and chemoresistance patterns. Because plastin genes play an important role in tumor cell invasion, adhesion, and migration, functional variations in these genes may translate into direct effects on prognosis in patients with locally advanced colon cancer. To test this hypothesis, we performed a comprehensive study using both a training and validation set to evaluate associations between six functional PLS3 (4) and LCP1 (2) polymorphisms with clinical outcomes, including time to tumor recurrence (TTR), in patients with colon cancer treated with adjuvant chemotherapy. Finally, we explored whether PLS3 and LCP1 polymorphisms demonstrated gender-or stage-specific differences and if such differences correlated with clinical outcomes.
Materials and Methods

Eligible patients
A total of 234 patients with stage III and high-risk stage II colon cancer were included in this study as the training set [USC (University of Southern California) cohort; Table 1 ]. High-risk stage II disease was defined by the presence of any of the following: T4 tumor, positive surgical margins, grade 3 or 4 histology in the absence of Microsatellite instability (MSI)-high status, perforation, obstruction, lymphovascular or perineural invasion, or fewer than 12 lymph nodes sampled at the time of surgical resection (15) . All patients were treated with 5-fluorouracil (5-FU)-based adjuvant chemotherapy at the Norris Comprehensive Cancer Center/University of Southern California (NCCC/USC; Los Angeles, CA) or the Los Angeles County/USC-Medical Center (LAC/USCMC; Los Angeles, CA) from 1987 to 2007. For the validation set (Table 1 ), a total of 498 patients with histologically confirmed stage II (both high-risk and low-risk tumors) and stage III colon cancer treated at the Division of Clinical Oncology, Department of Medicine, Medical University of Graz (MUG; Graz, Austria) from 2000 to 2009 were included. All patients were treated with a 5-FU-based regimen. All patients were included in the colon cancer surveillance program of NCCC/USC, LAC/USCMC, or MUG, providing the following information: history and physical examination and carcinoembryonic antigen levels every 3 months for 3 years and every 6 months at years 4 and 5 after surgery; colonoscopy at year 1 and thereafter every 3 to 5 years; and computed tomography scans of chest and abdomen every 6 months for the first 3 years. Patient data were collected retrospectively through chart review. Whole blood was collected at the time of diagnosis and stored at À80 C. The study was approved by the Institutional Review Boards of MUG and USC, and all study participants signed informed consent for the analysis of molecular correlates.
Candidate polymorphisms
Stringent predefined criteria were used to select candidate single-nucleotide polymorphisms (SNP) and included (i) polymorphisms, which could alter gene function in a biologically relevant manner [as predicted by the functional-SNP (F-SNP) database; refs. 16, 17] , and (ii) a minor allele frequency !10% in Caucasians (with relative allelic frequencies of polymorphisms in different ethnicities obtained from the genetics section in the Ensembl Genome Browser: http://uswest.ensembl.org/index.html). This study focused on testing the potentially functional genetic variants located at the 5 0 UTR (untranslated region), 3 0 UTR, or coding region, as well as tagging SNPs (Supplementary Table S1 ).
Genotyping
Genomic DNA was extracted from peripheral blood using the QIAmp Kit (Qiagen) and according to the manufacturer's instructions (www.qiagen.com). For the USC cohort, the candidate polymorphisms were tested using PCR-based direct DNA sequence analysis. Briefly, forward and reverse primers were used for PCR amplification. PCR fragments were sequenced on an ABI 3100A Capillary Genetic Analyzer (Applied Biosystems) and analyzed in either sense or antisense directions for the presence of the polymorphism. DNA sequence analyses were performed using the ABI Sequencing Scanner v1.0 (Applied Biosystems). The investigator analyzing the germline polymorphisms was blinded to the clinical dataset. For the MUG cohort, genotypes were centrally determined by a 5 0 -exonuclease assay (TaqMan) at the MUG. Primer and probe sets were designed and manufactured using Applied Biosystems "Assay-by-Design" custom service (Applera). General TaqMan reaction conditions were according to the manufacturer of the assays. Endpoint fluorescence was measured in a Lambda Fluoro 320 plus plate reader (MWG Biotech AG) using excitation/emission filters of 485/530 nm and 530/572 nm, respectively. In the plot, genotype groups were identified as separate and distinguishable clusters. To ensure methodologic consistency and quality control, genotype determination was repeated in at least 96 randomly selected samples.
Statistical analysis
The primary endpoint of this study was TTR, which was computed from the date of diagnosis of colon cancer to the date of the first documented tumor recurrence. If tumor recurrence was not observed, TTR was censored at the time of death or at the last follow-up. Deviation from the Hardy-Weinberg equilibrium for allelic distributions of PLS3 and LCP1 SNPs was tested using a 1-degree-offreedom c 2 . The relationships between PLS3 and LCP1 SNPs and baseline patient and tumor characteristics were examined using a c 2 or Fisher exact test whenever appropriate. The associations between PLS3 and LCP1 SNPs and TTR were assessed using Kaplan-Meier curves and log-rank tests in the univariate analysis, and Cox regression models adjusting for stage and type of adjuvant therapy, stratified by race in the multivariate analysis. As the PLS3 gene is located on X chromosome, the analyses for all PLS3 SNPs were conducted separately by gender. We tested the hypothesis that plastin polymorphisms predict time to recurrence in patients with stage II or III colon cancer in our USC institutional cohort first. These findings were then validated in an independent cohort. Concordance probability estimates (CPE) for the Cox proportional hazards model were calculated to evaluate the incremental contribution in discrimination provided by the PLS3 and LCP1 SNPs over the baseline prognostic factors in both cohorts (18) . SAS 9.3 (SAS Institute) and R package "CPE" were used to perform all the analyses. All tests were two-sided at a significance level of 0.05.
Results
The baseline characteristics of the training set and validation set patients included in this analysis are summarized in Table 1 . All genotype frequencies for plastin polymorphisms analyzed were within the Hardy-Weinberg equilibrium (P > 0.05).
Training set
A total of 234 USC patients with stage II and III colorectal cancer were included in this analysis as the training set (14) . The median overall survival (OS) for this cohort has not yet been reached. Patients with stage III disease were more likely to present with recurrence, compared with patients with high-risk stage II disease (log-rank P<0.001). We did not observe any significant associations between other demographic and clinicopathologic variables and TTR. In the USC cohort, plastin polymorphisms were not significantly associated with age, clinical (type of chemotherapy administered) or pathologic characteristics (tumor stage, grade, or lymph node status; P > 0.05).
Validation set
To validate our results, we performed an analysis of the polymorphisms, PLS3 rs6643869 and LCP1 rs4941543, in an independent Austrian cohort of 498 patients with stage II and III colorectal cancer. Baseline patient characteristics, tumor biologic factors, and therapeutic modalities are shown in Table 1 . The median age at the time of diagnosis was 66 years (range, 27-95 years). The median follow-up time was 64 months (range, 1-186 months). The median OS of this cohort was 15.3 years (95% CI, 9.7-15.5þ years).
SNP analysis
Training set. Genotyping of PLS3 rs6643869 and LCP1 rs4941543 was successful in 180 (77%) of the 234 patients. In the remaining 54 (23%) cases, there was limited quantity and/or quality of extracted genomic DNA. As the PLS3 gene is located on the X chromosome, data were analyzed separately for men and women for the PLS3 polymorphism. In univariate analysis, PLS3 rs6643869 and LCP1 rs4941543 were significantly associated with TTR. Female patients with the PLS3 rs6643869 A/A genotype had a shorter median TTR of 1.7 years (95% CI, 0.7-5.9þ years) than those with the A/G or G/G genotypes, who had a median TTR of 9.4 years (95% CI, 5.4-12.2þ years; HR, 2.84; 95% CI, 1.32-6.10; P ¼ 0.005; log-rank test; Fig. 1 , top; Table 2 ). We further analyzed female patients with PLS3 rs6643869 by tumor location. Both sides (right and left) have similar results (Supplementary Fig. 1 ). All patients with the LCP1 rs4941543 C/C genotype had a longer median TTR of 10.7 years (95% CI, 5.7-16.8þ years) compared with those with the C/T and T/T genotypes, who had a median TTR of 4.9 years (95% CI, 2.0-9.0þ years; HR, 1.83; 95% CI, 1.01-3.30; P ¼ 0.040; log-rank test; Fig. 1 , bottom; Supplementary Table  S2 ). In addition, male patients with the LCP1 rs11342 T allele had a longer median TTR of 7.1 years (95% CI, 4.9-11.4þ years), relative to men with the G/G genotype who had a median TTR 2.3 years, (95% CI, 1.5-6.8þ years; HR, 0.51; 95% CI, 0.25-1.04; P ¼ 0.042) in univariate analysis ( Supplementary Fig. S2 and Supplementary Table S2 ).
The multivariate model for the USC cohort was adjusted for stage and type of chemotherapy as covariates and stratified by race and gender. The A/A genotype (n ¼ 14) of PLS3 rs6643869 demonstrated a nonsignificant trend toward decreased TTR (HR, 2.26; 95% CI, 0.97-5.31; adjusted P ¼ 0.06) compared with patients with the A/G or G/G genotypes (n ¼ 68) in female patients (Table 2) . CPE was 0.728 (SE, 0.039) and 0.741 (SE, 0.037) for the multivariate model, including baseline patient prognostic factors only (baseline model), and adding PLS3 rs6643869 into the model among female patients, respectively. LCP1 rs4941543 was not associated with TTR in multivariate analysis (adjusted P ¼ 0.11) in any population. However, amongst female patients, those with the C/C genotype had a lower risk of recurrence than carriers of the T allele (HR, 2.95; 95% CI, 1.10-7.90; adjusted P ¼ 0.031). CPE was 0.769 (SE, 0.034) for LCP1 rs4941543-added multivariate model and 0.744 (SE, 0.034) for the baseline model. There were no statistically significant differences between the PLS3 rs6643869, LCP1 rs4941543, and LCP1 rs11432 polymorphisms and TTR in male patients ( Supplementary Fig. S3 and Supplementary Table S2 ). These data suggest that the PLS3 rs6643869 and LCP1 rs4941543 polymorphisms may serve as gender-based prognostic factors. We did not observe statistically significant associations between the other tested genes with regard to time to disease relapse (Supplementary Table S3 ).
Validation set. In the overall population analysis, the PLS3 rs6643869 and LCP1 rs4941543 polymorphisms were not associated with TTR in the validation set. However, when patients were stratified by gender, tumor location, and stage, the PLS3 rs6643869 and LCP1 rs4941543 polymorphisms demonstrated the following significant relationships:
1) In right-sided colorectal cancer, female patients with any G allele of PLS3 rs6643869 had an increased TTR (13.7þ years) compared with the G/A and A/A genotypes (3.3 years; Fig. 2 Table 3 , bottom). CPE was 0.650 (SE, 0.029) and 0.667 (SE, 0.028) for the baseline multivariate and LCP1 rs4941543-added model, respectively. These data are in contradiction to that found in our USC training cohort, which showed the C/C genotype to correlate with decreased risk of recurrence. 3) In stage III colorectal cancer, female patients with the LCP1 rs4941543 C/C genotype had a significantly decreased TTR (4.1 years) than carriers of the T allele in univariate analysis (10.6 years; HR, 0.47; 95% CI, 0.23-0.96; P ¼ 0.031), with a similar but nonsignificant trend in multivariate analysis (HR, 0.49; 95% CI, 0.24-1.01; P ¼ 0.052; Table 4 ). These data support the role of LCP1 rs4941543 as a prognosticator based on gender and tumor stage.
Discussion
In this study, we demonstrated that germline polymorphisms within the PLS3 and LCP1 genes are significantly associated with TTR in patients with locally advanced colon cancer treated with adjuvant chemotherapy. Moreover, when stratified by gender, the PLS3 rs6643869 and LCP1 rs4941543 polymorphisms correlate with TTR in women. The correlation between clinical outcomes and PLS3 rs6643869 was validated in an independent Austrian cohort. To our knowledge, this is the first report suggesting a relationship between PLS3 and LCP1 polymorphisms and clinical outcomes in stage II/III patients with colon cancer that is dependent upon gender, tumor location, and stage. These findings suggest that plastins may serve as a useful prognostic biomarker and warrant further investigation.
Our study identified several SNPs in the PLS3 and LCP1 genes that may play a significant role in predicting outcomes of stage II/III patients with colon cancer. Patients with the PLS3 rs6643869 polymorphism A/A genotype in the intron region of the PLS3 gene had a significantly higher risk of tumor recurrence than patients carrying at least one G allele in both the training and validation sets. Patients carrying the LCP1 rs4941543 polymorphism C/C genotype in the exon region of the LCP1 gene had a significantly lower risk of tumor recurrence than patients possessing either C/T or T/T in our training set. However, our validation set showed an opposite relationship between the C/C genotype and outcomes. This discrepancy could be attributed to two reasons. First, differences in ethnicity between the two populations may translate into contrasting pharmacogenomic interactions or activation of alternate pathways that affect tumor cell biology and behavior. Second, although the training set included only high-risk stage II patients, the validation cohort included both high-and low-risk stage II patients (as we could not discern high-or low-risk status from the available clinical data). Low-risk stage II patients may have a longer TTR and are more likely to live long enough to develop a recurrence.
The molecular mechanisms by which plastin polymorphisms affect tumor behavior and recurrence are under investigation. Modulations of transcription, interconnected stem cell pathways, and treatment-related factors have all been implicated. With regard to transcription, we know that the PLS3 rs6643869 polymorphism is located at intron 2 of the PLS3 gene, and the SNP functional prediction tool (F-SNP) has shown that a single nucleotide change from A to G may alter transcription factor binding of this gene. For example, PLS3 rs6643869 containing the G allele but not the A allele binds two transcription factors, Tst-1 and HSF, which may affect subsequent transcriptional activity in a process known as intron-mediated enhancement. With regard to the LCP1 rs4941543 polymorphism located at exon 18, a missense mutation from C to T renders an amino acid change from lysine (K) to glutamine (E), which may lead to potential functional alterations. Moreover, our findings suggest that PLS3 rs6643869 and LCP1 rs4941543 are gender-specific markers, which may imply further hormonal interactions. The fact that PLS3 maps to X.q23 may partly account for its gender-specific effect, but additional studies are needed to better elucidate the mechanisms underlying these associations.
Once deranged transcription has occurred, plastins may then mediate colon cancer metastasis through two distinct mechanisms. The first involves the epithelialmesenchymal transition (EMT), which is critical for cancer development and metastasis (19, 20) . A key effector of this transition is E-cadherin, and E-cadherin expression levels have reliably demonstrated an inverse correlation with tumor invasiveness. It follows that loss of E-cadherin expression occurs at sites of EMT during tumor progression (21, 22) . Therefore, one possibility is that overexpressed PLS3 and LCP1 in colon cancer cells lead to loss of E-cadherin (10, 11) and thereby promotes b-catenin release through the Wnt signaling pathway (23, 24) , facilitating passage through the EMT. Alternatively, plastin overexpression may enhance cell motility by modifying the actin cytoskeleton and, in doing so, increase metastatic potential.
Studies using colorectal cancer cell lines have shown a promising link between PLS3, the EMT, and tumor metastasis. Willis and colleagues (10) showed that lamina A, a putative colon stem cell biomarker, can induce PLS3 upregulation, which in turn leads to E-cadherin downregulation and increased tumor invasiveness. Furthermore, a recent study led by Yokobori and colleagues reported that PLS3 itself may be a novel circulating tumor cell (CTC) marker expressed during the EMT, and the detection of PLS3-positive CTCs was found to be an independent prognostic factor in patients with metastatic colorectal cancer (25) . Our study showed that PLS3 plasma concentration was significantly higher in patients with colorectal cancer than in control patients with no evident disease (NED; Supplementary Fig. S4 ), which is consistent with previous studies, and suggests that PLS3 expression may serve as a surrogate for tumor invasiveness in stage II/III colorectal cancer.
Other studies have similarly demonstrated a connection between LCP1, E-cadherin-mediated tumor spread, and poor prognosis in colon cancer. Elevated LCP1 levels in cancer cell lines and solid tumors have been correlated with increased migration, invasion, and metastatic potential (12, 26, 27) . In colorectal cancer, several independent studies have confirmed that L-plastin protein overexpression is also a marker for aggressive disease and poor prognosis (28, 29) . Foran and colleagues (11) showed that colorectal cancer cell lines overexpressing LCP1 acquire invasiveness through E-cadherin downregulation, which induces dedifferentiation, invasion, and metastasis. Furthermore, others (29, 30) have shown that LCP1 correlates with tumor protein expression and colorectal cancer progression using immunohistochemical analysis and ELISA, which is consistent with our results in the USC cohort. Our data showed that LCP1 plasma concentration was much higher in patients with colorectal cancer than in control patients with NED. Moreover, LCP1 was higher in stage III than in stage II patients, suggesting that LCP1 expression may be related to lymph node metastasis ( Supplementary Fig. S3 ).
In addition to affecting the intrinsic invasiveness of tumor cells, PLS3 has been implicated in modulating chemotherapeutic efficacy. Specifically, enhanced PLS3 expression has been associated with both chemotherapy and radiotherapy resistance in cancer cells (31, 32) . Hisano and colleagues reported that PLS3 downregulation led to increased sensitivity to cisplatin in platinumresistant cell lines. In our future studies, we will focus on the correlation between plastin expression levels and the presence of LCP1 or PLS3 polymorphisms. The PLS3 rs6643869 and LCP1 rs4941543 polymorphisms, in particular, may alter gene function/expression, thereby increasing PLS3 and LCP1 levels and promoting Wnt signaling through the E-cadherin/b-catenin complex, ultimately resulting in colorectal cancer recurrence and progression.
In summary, this study provides the first evidence that germline genetic variants of the PLS3 and LCP1 genes predict tumor recurrence and time to disease relapse in a gender-and stage-specific manner. The PLS3 rs6643869 SNP retained a significant correlation with outcomes after adjusting for multiple variables and has now been confirmed in a validated cohort. Taken together, our data strengthen the role of plastin proteins in locally advanced colorectal cancer and may aid in the selection of patients who would benefit from plastin-targeted treatments in the future.
